AI Advisor v2.8.0 — Two New Features

Ask Anything & Manual Peer Selection

NotebookLM-style Q&A for Indian Stocks + Fix for Screener.in's Wrong Peer Groupings

Template 9: Ask Anything • Innova Captab Case Study • GICS Peer Override

Following along? Install the extension first

Finmagine AI Advisor — free • no account needed • Chrome, Edge, Brave

Install Free →
Published: March 13, 2026  •  Finmagine Research Team  •  22 Flashcards  •  Best with: Claude (Ask Anything)  •  Claude / ChatGPT (Peer Comparison)
THE PROBLEMS

Two Problems, Two Solutions

Finmagine AI Advisor v2.8.0 ships two independent upgrades. They solve different problems, but both come from the same root cause: Screener.in is a data platform, not an answer platform. It shows you tables and documents. It does not answer your questions.

Problem 1 — The Research Rabbit Hole

You are looking at Innova Captab. Management mentioned their Jammu facility ramp-up in every concall for the last three quarters. You want the numbers: what is the revenue contribution from Jammu, how much capex has been invested, what is the optimal capacity and timeline? All of this is in the concall transcripts.

But Screener.in gives you a list of 12 PDF links. Not answers. You would need to open each PDF, search for relevant passages, cross-reference across quarters, reconcile different numbers. That is 45 minutes of document work before you can think about the investment question.

v2.8.0 Solution: The Ask Anything template. Type your question in plain English, click Build Prompt, paste into Claude. Claude reads all the PDFs and returns structured FINDING blocks with exact source citations — quarter, document name, and a single factual point per finding. 45 minutes of document work done in under 2 minutes.

Problem 2 — Wrong Peers

Screener.in auto-detects peer companies using GICS sector codes. For large-cap sectors with clean sub-industry definitions — IT Services, Private Banking, FMCG — this works well. TCS gets Infosys and Wipro. HDFC Bank gets ICICI Bank and Kotak.

But for mid-cap and specialized sub-sectors, GICS granularity breaks down. Innova Captab is a pharma contract development and manufacturing organization (CDMO). It gets grouped with Divi's Laboratories and Cipla — an API manufacturer and a branded generic company respectively. Neither is a CDMO. Comparing Innova Captab's margins and capital intensity to Divi's or Cipla produces a misleading peer analysis. The right peers are Akums Drugs and Windlas Biotech.

v2.8.0 Solution: Manual Peer Selection. Before the Peer Comparison template fetches any data, it now shows a selection UI where you can deselect irrelevant auto-detected peers and type custom NSE codes. Type AKUMS, WINDLAS and the analysis runs on the right peers.
FeatureProblem SolvedTemplateBest AI
Ask Anything (AMA) NEWManual PDF searching across 12+ concalls and annual reportsTemplate 9 (India)Claude
Manual Peer Selection NEWGICS-based wrong peer groupings from Screener.inTemplate 7 (Peer Comparison)Claude / ChatGPT
ASK ANYTHING

Ask Anything — How It Works

The NotebookLM Problem Statement

When NotebookLM launched, users immediately grasped its core insight: upload documents, ask questions, get citations. It became the go-to tool for reading long PDFs efficiently. The same need exists for Indian stock research. Every investor with a Screener.in premium account has access to a company's complete document library. What was missing was a structured way to ask questions against that library from within the same research workflow.

"Works like NotebookLM — reads all annual reports and concalls, answers with citations."

That is the design requirement for Ask Anything. The extension already has access to all document URLs for every company through the Finmagine Data Layer. v2.8.0 bundles those URLs into a targeted Q&A prompt with strict citation-only instructions and sends it to Claude.

What the Template Does

When you open the Ask Anything template on any Screener.in company page, the extension shows:

  1. Document summary pill — a count of available documents for this company: e.g., "12 concall quarters, 8 annual reports, 6 credit ratings available." This tells you before you even type a question how rich the document base is.
  2. Free-form question textarea — type any question in plain English. Single focused questions work best.
  3. Five click-to-fill example questions to help users who are not sure what to ask.
  4. BUILD PROMPT button — generates a structured prompt with your question + all document URLs + strict FINDING format instructions.

Example Question 1

"What did management say about capacity expansion plans in the last 3 concalls?"

Example Question 2

"What are the main risks mentioned in the latest annual report?"

Example Question 3

"How has working capital trend changed over the last 3 years according to management?"

Example Question 4

"What regulatory approvals has the company received or applied for recently?"

Example Question 5

"What is management's guidance for revenue and margins for the next 2 years?"

The FINDING Format

The prompt instructs Claude to respond exclusively in a structured citation format. No narrative paragraphs, no synthesis, no generic observations — only numbered FINDING blocks. Each block has exactly two fields: Source (the document name and period) and Finding (one specific factual point with exact numbers or direct quotes).

--- Expected Claude output format --- FINDING 1 Source: Q3 FY26 Concall Transcript Finding: [One specific factual point with exact numbers or quotes] FINDING 2 Source: Q2 FY26 Concall Transcript Finding: [One specific factual point with exact numbers or quotes] ... (continue for all relevant findings) ...
Why This Format? The FINDING/Source/Finding structure prevents two common AI failure modes: (1) hallucination — every claim must be tied to a specific document the AI can reference, and (2) synthesis drift — the AI cannot blend two different quarters' data together into a single misleading statement. Every finding is atomic and traceable.

Why Claude, Not Gemini Deep Research?

Gemini Deep Research is designed to produce comprehensive research reports. That design goal conflicts directly with the Ask Anything use case. Gemini Deep Research will receive the AMA prompt, recognize it as a research question about a company, and produce a full multi-section report regardless of format instructions. It ignores the FINDING structure because its training objective is comprehensive coverage, not targeted Q&A.

Claude is trained to follow structured output instructions. When the AMA prompt says "respond only in FINDING blocks, one fact per finding," Claude complies. The output is a clean numbered list of citations — exactly what makes the template useful for rapid document research.

For this reason, the Ask Anything template card in the extension UI shows: ✦ Best with: Claude. All other templates retain their existing BEST_WITH recommendations.

One Focused Question Works Best: Ask Anything is designed for targeted retrieval, not open-ended research. "Tell me everything about this company" will produce a diffuse output with low information density per finding. "What did management say about the Jammu facility ramp-up in the last 3 concalls?" produces 10 dense, citation-backed findings in under 2 minutes.
CASE STUDY

Innova Captab — Ask Anything in Practice

To demonstrate Ask Anything with a real example, we ran the template on Innova Captab (NSE: INNOCAP) with the following question:

"What did management say about capacity expansion plans in the last 3 concalls?"

Claude read the Q1 FY26, Q2 FY26, and Q3 FY26 concall transcripts and returned 11 FINDING blocks in under 2 minutes. Here is the complete output:

FINDING 1
Source: Q1 FY26 Concall Transcript
Jammu (Kathua) facility commenced commercial operations in January 2025 and gained momentum during the quarter. MD stated: "Our newly commissioned facility in Jammu gained momentum during the quarter, and we expect this traction to accelerate in the coming quarters and beyond." The Jammu complex has 4 manufacturing blocks: cephalosporin, penicillin, penum, and BFS.
FINDING 2
Source: Q1 FY26 Concall Transcript
Existing facilities at Baddi, Dehradun, and Taloja are operating at 55–60% capacity utilization with room for 15–25% organic growth without requiring major additional capex.
FINDING 3
Source: Q2 FY26 Concall Transcript
Total capex invested in the Jammu facility exceeded ₹480 crores. At optimal capacity utilization (65–70%), the facility's revenue potential is ₹1,400 crores+. Management guided a ramp-up horizon of 3–4 years from January 2025.
FINDING 4
Source: Q2 FY26 Concall Transcript
Full-year Jammu revenue guidance was revised downward from ₹400 crores to ₹270–280 crores due to two factors: (1) GST rate reduction on medicines manufactured in Jammu from 12% to 5%, and (2) API price corrections in the broader market.
FINDING 5
Source: Q2 FY26 Concall Transcript
The adverse GST impact is expected to neutralize over 2–3 years as Jammu scales. The facility also receives a 6% interest subvention on term loans for plant and machinery under the Government of India's J&K incentive scheme.
FINDING 6
Source: Q2 FY26 Concall Transcript
Management guided a 20%+ long-term growth trajectory for the overall business, targeting to double both top-line and EBITDA within 3 years. Exact quote: "Historically, we have doubled our top-line every 3 to 4 years."
FINDING 7
Source: Q3 FY26 Concall Transcript
Jammu revenue grew from ₹60 crores in Q2 FY26 to ₹89 crores in Q3 FY26 — a sequential increase of 48%. The facility is nearing EBITDA breakeven but has not yet achieved PAT breakeven.
FINDING 8
Source: Q3 FY26 Concall Transcript
Baddi and Dehradun/Taloja facilities remain at 55–60% utilization with 15–25% organic growth headroom, consistent with guidance from Q1 FY26.
FINDING 9
Source: Q3 FY26 Concall Transcript
Jammu optimal capacity target reiterated at 65–75% utilization. Peak revenue potential at optimal capacity reiterated at ₹1,400 crores+. Ramp-up timeline maintained at 3–4 years from January 2025.
FINDING 10
Source: Q3 FY26 Concall Transcript
Management guided 20% overall revenue growth for FY27, with Jammu playing a significant role. Future expansions beyond FY28 are planned but no specific details have been disclosed.
FINDING 11
Source: Q3 FY26 Concall Transcript
Two regulatory milestones: (1) UK MHRA GMP certification for the cephalosporin plant in Baddi received after inspection on August 18–20, 2025, with zero critical or major observations. (2) Jammu facility cleared a Ukraine SMDC inspection, enabling regulated market export capacity ramp-up from the new plant.

What This Demonstrates

Eleven findings, all citation-backed, all traceable to a specific quarter. No hallucinations — every number matches what management actually stated. The exact revenue progression (₹60 Cr in Q2 → ₹89 Cr in Q3), the capex figure (₹480 Cr+), the revenue potential (₹1,400 Cr+ at 65–70% utilization), and the revised guidance (₹270–280 Cr from ₹400 Cr) are all direct citations, not AI-constructed summaries.

A Note on BSE PDFs: Claude will transparently flag when BSE-hosted PDFs are inaccessible. BSE India blocks programmatic PDF access with HTTP 403 errors. When this happens, Claude falls back to GuruFocus earnings highlights, Yahoo Finance transcript summaries, and NSE-hosted versions of the same documents, clearly marking which source type each finding came from. This transparency is intentional — you always know which claims are from primary documents and which are from secondary sources.
MANUAL PEER SELECTION

Manual Peer Selection — How It Works

The GICS Problem

Screener.in auto-detects peers from the Peers table on each company page. The grouping algorithm uses GICS (Global Industry Classification Standard) sector codes. At the broad sector level — Information Technology, Consumer Staples, Financials — GICS is accurate. But at the sub-industry level, GICS has known blind spots for Indian mid-cap companies with specialized business models.

A pharma CDMO (Innova Captab), a pharma API manufacturer (Divi's Laboratories), and a branded generic company (Cipla) can share the same GICS sub-industry code. Their business models are completely different: CDMO revenues are contract-based with lower volatility; API revenues track commodity chemical cycles; branded generic revenues depend on prescription volume and pricing power. Comparing margins, asset turns, and capital intensity across these three as "peers" produces misleading conclusions.

Previous Behavior (v2.7.0 and Earlier)

The Peer Comparison template auto-detected all peers from Screener's Peers table, immediately initiated data fetches from the Finmagine Data Layer for each peer, and showed a status panel. There was no way to override the peer list.

New Behavior (v2.8.0)

The Peer Comparison template now has a two-step flow. Step 1 is always shown before any data fetch:

Choose Your Comparison Peers

Auto-detected from Screener.in — uncheck any that are not relevant comparators:

✓ DIVISLAB ✗ CIPLA ✗ SUNPHARMA ✓ GRANULES
AKUMS, WINDLAS

If custom codes are provided, they replace the auto-detected list entirely.

Once you click "Analyze These Peers," the template proceeds to Step 2 — the same status panel as in previous versions, showing data fetch progress for each selected peer. A small "✐ Edit peers" button in the step 2 header lets you go back and change your selection without starting over.

Use Case Examples

Pharma CDMO

Innova Captab: deselect Divi's / Cipla, add AKUMS, WINDLAS. Now comparing CDMO to CDMO on contract revenue mix, utilization rates, and regulated vs domestic market split.

Specialty Chemicals

Mid-cap specialty chem: keep 2 of 6 auto-detected peers that are true specialty players, add NOCIL as a more relevant comparator. Removes commodity chemical noise from the analysis.

SME IPO or Recent Listing

Recently listed company: Screener auto-detects wrong peers because the stock has been live for less than one full reporting cycle. Override entirely with manually researched NSE codes.

Data Layer Coverage: The Finmagine Data Layer caches fundamentals for most Nifty 500 stocks, updated whenever any user visits those stocks on Screener.in. Custom peers you type will show a warning icon (⚠) in the step 2 status panel if they are not yet cached. The analysis still proceeds — Claude uses what it can access from the document URLs.
PLATFORM GUIDANCE

Why Claude for Ask Anything

The four AI platforms supported by Finmagine AI Advisor have different design goals. Understanding which platform fits which template type makes a material difference in output quality.

AI PlatformDesign GoalBest TemplatesAMA Suitability
Gemini Deep Research Comprehensive reports with web grounding Comprehensive, Management Quality, Deep Research, Forensic Governance Poor — ignores format constraints, always produces a full research report
Claude Instruction-following, structured output Ask Anything, Investor Panel, Risk-Reward, Peer Comparison Excellent — follows FINDING format precisely, one fact per block
ChatGPT General-purpose analysis Quarterly, Risk-Reward, Peer Comparison Moderate — may add narrative bridges between findings
Perplexity Real-time web search + citations Quick lookups, current events context Moderate — useful if BSE PDFs are inaccessible, uses web fallback

Gemini Deep Research's training objective is to produce comprehensive coverage of a topic, not to follow a narrowly constrained output format. Even with explicit format instructions, it interprets the AMA prompt as a research question and produces a full multi-section report. This is by design — it is the right tool for Comprehensive Analysis and Forensic Governance. It is the wrong tool for targeted Q&A with atomic citations.

Claude follows structured output instructions faithfully because instruction adherence is a core capability it is explicitly trained for. The FINDING/Source/Finding format constraint is preserved across all 11+ findings in the Innova Captab output above — Claude never drifts into narrative even for complex multi-quarter questions.

Template Card Label: The Ask Anything card in the extension UI shows ✦ Best with: Claude (single platform). All other templates retain their existing BEST_WITH labels: Comprehensive and Deep Research show Gemini Deep Research; Investor Panel shows Claude / ChatGPT; Peer Comparison shows Claude / ChatGPT.
THE ECOSYSTEM

v2.8.0 in Context — The Full Template List

With v2.8.0, Finmagine AI Advisor has 13 analysis templates in total — 9 for Indian stocks on Screener.in and 4 for US/Global stocks on stockanalysis.com.

#TemplateFocusBest AI
1Comprehensive Analysis360° Five-Parameter assessment + unit economicsGemini Deep Research
2Risk-Reward AnalysisBull / base / bear scenarios, downside protectionClaude / ChatGPT
3Management QualityCapital allocation, governance, concall intelligenceGemini Deep Research
4Quarterly Deep-DiveLatest quarter trends, near-term outlookClaude / ChatGPT
5Deep Research9-part forensic with PDF document readingGemini Deep Research
6Forensic GovernanceRPTs, pledging, earnings call language, CAROGemini / Claude
7Peer ComparisonAuto-fetched sector peer data, 4-analyst scorecard + Manual Peer SelectionClaude / ChatGPT
8Investor Panel6 legendary investors debate the stock independentlyClaude / ChatGPT
9Ask Anything (AMA) NEWType any question, Claude answers with FINDING citations from all concalls and annual reportsClaude

US / Global Templates (4)

#TemplateFocus
1Forensic AnalysisZ-Score, F-Score, ROIC-WACC, governance
2Comprehensive Analysis360° US company assessment
3Risk-Reward AnalysisScenario analysis for US stocks
4Quarterly Deep-DiveLatest quarter + earnings context
Suggested Workflow with Ask Anything: Run Comprehensive Analysis first to get your overall view on a company → when a specific claim (e.g. management's capex guidance) needs verification, switch to Ask Anything with a targeted question → use the FINDING output to ground your thesis in direct management statements rather than secondhand summaries.

Test Your Knowledge — 22 Flashcards

Click any card to reveal the answer. Use the search box to find specific topics. Covers Ask Anything, Manual Peer Selection, the FINDING format, and the Innova Captab case study.

Free Chrome Extension

Ready to try this yourself?

Install the Finmagine AI Advisor and generate institutional-grade research prompts from any Screener.in or stockanalysis.com company page in seconds.

Install from Chrome Web Store →

No account required • Works on Chrome, Edge, Brave, Opera

Join Finmagine WhatsApp Community

Explore the Complete AI Advisor Hub

9 India templates + 4 US templates — including Ask Anything, Investor Panel, Forensic Governance, and Peer Comparison — with sector-aware intelligence, health scoring, and full document library Q&A.

Visit AI Advisor Hub →

Also From Finmagine

Financial Chart Builder
Transform Screener.in tables into interactive charts. 6-tab panel, valuation multiples, Scenario DCF. Free.
Finmagine Trader
NSE momentum scanner — Stage 2, VCP, Near 52W High. Scan 2,000+ stocks in seconds. Free.
Portfolio Manager
Multi-broker portfolio tracker with XIRR, per-broker stop-loss discipline, and cloud sync. Free.
← Back to Blog Hub